Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Efficacy of erenumab is sustained over more than 4 years of treatment

Publish date:: August 5, 2019

Key clinical point: Among patients with episodic migraine, more than 4 years of preventive treatment with erenumab may be effective, safe, and well tolerated.

Major finding: Patients’ average number of monthly migraine days at study baseline was 8.7; the average change from baseline to the most recent month in the interim analysis was –5.8.

Study details: Interim analysis of data from 250 patients who received erenumab for the preventive treatment of migraine for more than 4 years in an open-label extension study.

Disclosures: The study was sponsored by Amgen, and several study authors are employees of Amgen or Novartis, the companies that market erenumab. Dr. Ashina is a consultant for Amgen, Novartis, and other companies.

Citation:

Ashina M et al. AHS 2019, Abstract IOR10.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Headache & Migraine

HIT-6 may help track meaningful change in chronic migraine,

Choroid plexuses may play a role in migraine,

Multiple traits more common in difficult-to-treat patients with migraine,

Marijuana for migraine? Some tentative evidence,

Low vitamin D levels in patients with migraine,